MIM
CODX

MetLife Investment Management’s Co-Diagnostics CODX Stock Holding History

MetLife Investment Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-99
Closed -$28.2K – 2446
2021
Q1 		$28.2K Sell
99
-311
-76% -$124K ﹤0.01% 2297
2020
Q4 		$114K Hold
410
– – ﹤0.01% 2214
2020
Q3 		$167K Hold
410
– – ﹤0.01% 1968
2020
Q2 		$238K Buy
+410
New +$187K ﹤0.01% 1797

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MetLife Investment Management's CODX Position: Q2 2021 in Review

MetLife Investment Management sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 99 shares — an estimated $28.2K sold.

MetLife Investment Management first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $238K in Q2 2020. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • MetLife Investment Management reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • MetLife Investment Management sold 99 Co-Diagnostics shares in Q2 2021, an estimated $28.2K.
  • MetLife Investment Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • MetLife Investment Management's Co-Diagnostics position peaked at $238K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.